Oncolytics Biotech (ONCY) Loans - Gross (2009 - 2020)
Oncolytics Biotech (ONCY) posted quarterly Loans - Gross of $270.9 million for Q4 2016, down 100.0% year-over-year from $262218.2 billion in Q1 2016, and down 100.0% quarter-over-quarter from $262218.2 billion in Q4 2015.
Oncolytics Biotech (ONCY) Loans - Gross (2009 - 2020) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Loans - Gross for 8 consecutive years, with $270.9 million the latest figure, recorded in Q4 2016.
- In Q4 2016, Loans - Gross fell 100.0% year-over-year to $270.9 million; the TTM figure through Dec 2016 stood at $270.9 million (down 100.0% YoY), while the FY2016 annual figure was $270.9 million, down 100.0% from the prior year.
- Loans - Gross slipped to $270.9 million in Q4 2016 per ONCY's latest filing, from $262218.2 billion in the prior quarter.
- Across five years, Loans - Gross topped out at $262218.2 billion in Q4 2015 and bottomed at $2012.0 in Q3 2012.
- Historically, Loans - Gross has averaged $126414.8 billion across 5 years, with a median of $117520.4 billion in 2013.
- Annual changes were most pronounced in 2013 — Loans - Gross jumped 102856141.39% — and 2016, when it slumped 100.0%.
- Oncolytics Biotech's Loans - Gross stood at $228.5 million in 2012, then surged by 102856141.39% to $235040.5 billion in 2013, then advanced by 11.14% to $261229.7 billion in 2014, then rose by 0.38% to $262218.2 billion in 2015, then slumped by 100.0% to $270.9 million in 2016.
- Business Quant data shows ONCY's Loans - Gross at $270.9 million in Q4 2016, $262218.2 billion in Q4 2015, and $261229.7 billion in Q4 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Loans - Gross (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | - |
| 10 | Oncolytics Biotech | 97.22 Mn | 97.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 333,224.00 |
| Jun 30, 2020 | 402,013.00 |
| Dec 31, 2019 | 8.51 Mn |
| Dec 31, 2016 | 270.90 Mn |
| Dec 31, 2015 | 262,218.23 Bn |
| Dec 31, 2014 | 261,229.72 Bn |
| Dec 31, 2013 | 235,040.46 Bn |
| Dec 31, 2012 | 228.51 Mn |
| Sep 30, 2012 | 2,012.00 |
| Dec 31, 2011 | 198.05 Mn |
| Dec 31, 2010 | 740,754.00 |
| Sep 30, 2010 | 21.14 Mn |
| Jun 30, 2010 | 26.57 Mn |
| Mar 31, 2010 | 30.16 Mn |
| Dec 31, 2009 | 35.59 Mn |
| Sep 30, 2009 | 10.24 Mn |
| Jun 30, 2009 | 12.75 Mn |
| Mar 31, 2009 | 9.80 Mn |